eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine

Yougang Ren
1
,
Zhongxiao Wu
1
,
Mouzhe Yang
1
,
Haitao Lou
2

  1. Department of Dermatology, Ningbo No. 6 Hospital, Ningbo, Zhejiang Province, China
  2. Department of Pharmacy, Zhuji Maternal and Child Health Hospital, Zhuji, Zhejiang Province, China
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2024.146176
Online publish date: 2025/01/08
Article file
- Clinical curative.pdf  [0.16 MB]
Get citation
 
 
1. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc 2019; 40: 84-92.
2. Huang E, Ong PY. Severe atopic dermatitis in children. Curr Allergy Asthma Rep 2018; 18: 35.
3. Gerner T, Skov L, Thyssen JP. Atopic dermatitis. Ugeskr Laeger 2018; 180: V04170331.
4. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups – variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol 2018; 27: 340-57.
5. Tracy A, Bhatti S, Eichenfield LF. Update on pediatric atopic dermatitis. Cutis 2020; 106: 143-6.
6. Simon D, Wollenberg A, Renz H, Simon Hu. Atopic dermatitis: collegium internationale allergologicum (cia) update 2019. Int Arch Allergy Immunol 2019; 178: 207-18.
7. Zhou L, Liu W, Liu K, et al. Clinical characteristics of death and recovered cases of COVID-19 patients with endotracheal intubation. Acta Medica Mediterr 2021; 37: 833-9.
8. Kulthanan K, Tuchinda P, Nitiyarom R, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol 2021; 39: 145-55.
9. Matsunaga K, Katoh N, Fujieda S, et al. Dupilumab: basic aspects and applications to allergic diseases. Allergol Int 2020; 69: 187-96.
10. Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol 2022; 32: 97-115.
11. Silverberg JI, Thyssen JP, Fahrbach, K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797-810.
12. Simpson E, Bissonnette R, Eichenfield LF, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol 2020; 83: 839-46.
13. Chiarotto A, Maxwell LJ, Ostelo RW, et al. Measurement properties of visual analogue scale, numeric rating scale, and pain severity subscale of the brief pain inventory in patients with low back pain: a systematic review. J Pain 2019; 20: 245-63.
14. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-44.
15. Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The atopic dermatitis control tool: a high-performance tool for optimal support. Acta Derm Venereol 2021; 101: adv00618.
16. Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the dermatology life quality index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol 2019; 33: 123-7.
17. Saini S, Pansare M. New insights and treatments in atopic dermatitis. Pediatr Clin North Am 2019; 66: 1021-33.
18. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract 2020; 8: 91-101.
19. Seegräber M, Srour J, Walter A, Knop M. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018; 11: 467-74.
20. Jiang X, Hu YL, Wu YL, et al. Analysis of the effectiveness of preventive care in conjunction with the use of a flushable double-lumen stoma bag for the prevention of incontinent dermatitis in critically ill patients. Acta Medica Mediterr 2022; 38: 1759-63.
21. Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2020; 21: 567-77.
22. Gooderham MJ, Hong HCH, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78 (3 Suppl 1): S28-36.
23. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-93.
24. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA. Dermatol 2020; 156: 44-56.
25. Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2018; 90: 190-8.
26. Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022; 23: 365-83.
27. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. JAMA Dermatol 2019; 156: 44-56.
28. Paller AS, Simpson EL, Siegfried EC, et al.; participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022; 400: 908-19.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.